The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19.

OBJECTIVE: Vaccination against SARS-CoV-2 is essential to mitigate the personal, social and global impact of the coronavirus disease (COVID-19) as we move from a pandemic to an endemic phase. Vaccines are now required that offer broad, long-lasting immunological protection from infection in addition to protection from severe illness and hospitalisation. Here we present a review of the evidence base for a new COVID-19 vaccine, PHH-1V (Bimervax®; HIPRA HUMAN HEALTH S.L.U), and the results of an expert consensus. METHODS: The expert committee consisted of Spanish experts in medicine, family medicine, paediatrics, immunology, microbiology, nursing, and veterinary medicine. Consensus was achieved using a 4-phase process consisting of a face-to-face meeting during which the scientific evidence base was reviewed, an online questionnaire to elicit opinions on the value of PHH-1V, a second face-to-face update meeting to discuss the evolution of the epidemiological situation, vaccine programmes and the scientific evidence for PHH-1V and a final face-to-face meeting at which consensus was achieved. RESULTS: The experts agreed that PHH-1V constitutes a valuable novel vaccine for the development of vaccination programmes aimed towards protecting the population from SARS-CoV-2 infection and disease. Consensus was based on evidence of broad-spectrum efficacy against established and emerging SARS-CoV-2 variants, a potent immunological response, and a good safety profile. The physicochemical properties of the PHH-1V formulation facilitate handling and storage appropriate for global uptake. CONCLUSIONS: The physicochemical properties, formulation, immunogenicity and low reactogenic profile of PHH-1V confirm the appropriateness of this new COVID-19 vaccine.

Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test

No disponible

El déficit selectivo de inmunoglobulina A excepcionalmente se asocia a esclerosis múltiple / Selective immunoglobulin A deficiency is exceptionally associated with multiple sclerosis

No disponible

Allergy to asticot maggots. Identification of allergens.

UNLABELLED: There are some written reports of allergic reactions after contact with Asticot larvae in anglers and occupationally exposed workers. Clinical and immunological studies were performed to confirm the allergens involved in the case of a 12-year-old male who developed respiratory symptoms shortly after contact with Asticot maggots used as fish bait. METHODS AND RESULTS: Aqueous extracts of Asticot maggots were taken for in vivo and in vitro tests. The protein concentration as determined by turbidimetric assay was 1.4 mg/ml. Skin prick test with Asticot extract was positive with an immediate response. Ten atopic and ten nonatopic control subjects did not react to the extract. Specific serum IgE antibodies against Asticot were found in the patient's serum (ELISA). Coomasie staining after SDS-PAGE separation of Asticot extract showed three protein bands of 30, 40 and 60 kDa. IgE immunoblot showed one antigenic band of 60 kDa specifically recognized by the patient's IgE. Specific nasal challenge test with Asticot extract using a Rhinospir 164 rhinomanometer showed immediate response (1/10 w/v), with a 200% increase in nasal resistances from baseline. CONCLUSIONS: One main allergen of MW 60 kDa was specifically recognized by our patient's IgE. There are no previous reports in the literature that characterize the allergens involved in Asticot hypersensitivity. Asticot maggots should be taken into account as a possible causative agent of respiratory symptoms due to a type I hypersensitivity mechanism in anglers who are exposed to emanations of these live fish baits.

Allergy to asticot maggots. Identification of allergens

There are some written reports of allergic reactions after contact with Asticot larvae in anglers and occupationally exposed workers. Clinical and immunological studies were performed to confirm the allergens involved in the case of a 12-year-old male who developed respiratory symptoms shortly after contact with Asticot maggots used as fish bait. Methods and results: Aqueous extracts of Asticot maggots were taken for in vivo and in vitro tests. The protein concentration as determined by turbidimetric assay was 1.4 mg/ml. Skin prick test with Asticot extract was positive with an immediate response. Ten atopic and ten nonatopic control subjects did not react to the extract. Specific serum IgE antibodies against Asticot were found in the patient's serum (ELISA). Coomasie staining after SDS-PAGE separation of Asticot extract showed three protein bands of 30, 40 and 60 kDa. IgE immunoblot showed one antigenic band of 60 kDa specifically recognized by the patient's IgE. Specific nasal challenge test with Asticot extract using a Rhinospir 164 rhinomanometer showed immediate response (1/10 w/v), with a 200 % increase in nasal resistances from baseline. Conclusions: One main allergen of MW 60 kDa was specifically recognized by our patient's IgE. There are no previous reports in the literature that characterize the allergens involved in Asticot hypersensitivity. Asticot maggots should be taken into account as a possible causative agent of respiratory symptoms due to a type I hypersensitivity mechanism in anglers who are exposed to emanations of these live fish baits (AU)

Hay publicados algunos casos de reacciones alérgicas tras contacto con larvas de Asticot en pescadores aficionados o en trabajadores expuestos a las mismas por su profesión. Se presentan los estudios clínicos e inmunológicos efectuados para demostrar los alergenos implicados, en este caso de un niño de 12 años de edad con síntomas respiratorios tras el contacto con larvas de Asticot usadas como cebo para la pesca. Métodos y resultados: Se prepararon extractos acuosos de larvas de Asticot para su utilización en los estudios in vivo e in vitro. La concentración proteica del extracto por turbidimetría fue de 1,4 mg/ml. El prick test con extracto de Asticot fue positivo en lectura inmediata, con controles negativos (10 pacientes atópicos y 10 personas no atópicas). Por ELISA se demostró la presencia de IgE sérica específica frente al extracto de Asticot. La tinción con azul de Coomasie tras la separación del extracto de Asticot por electroforesis en SDS-PAGE muestra tres bandas con PM aproximado de 30, 40 y 60 kDa. La inmunotransferencia IgE mostró una banda antigénica de 60 kDa reconocida específicamente por la IgE del paciente. La provocación nasal específica con el extracto produjo una respuesta inmediata con un incremento del 200 por ciento de la resistencia nasal medida con el rinomanómetro Rhinospir 164. Conclusiones: Hemos demostrado un alergeno principal de 60 kDa reconocido de forma específica por la IgE del paciente. No hay trabajos publicados que identifiquen los alergenos implicados en las reacciones de hipersensibilidad por Asticot. Las larvas de Asticot deben ser tenidas en cuenta como posibles agentes etiológicos de reacciones alérgicas en aficionados a la pesca y en quienes estén expuestos a las emanaciones de este tipo de cebos de pesca vivos (AU)